Shares of ProMetic Life Sciences Inc. (TSE:PLI – Get Free Report) traded up 0.2% on Tuesday . The stock traded as high as C$13.72 and last traded at C$13.60. 921 shares traded hands during trading, a decline of 88% from the average session volume of 8,002 shares. The stock had previously closed at C$13.57.
ProMetic Life Sciences Stock Up 0.2 %
The business has a fifty day moving average price of C$13.60. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 37.47. The firm has a market cap of C$317.06 million and a PE ratio of -0.22.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Further Reading
- Five stocks we like better than ProMetic Life Sciences
- Golden Cross Stocks: Pattern, Examples and Charts
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Comparing and Trading High PE Ratio Stocks
- Netflix Is On Track To Hit $1,000 By Christmas
- What is the FTSE 100 index?
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
